According to a scientific committee (SCENIHR) mandated by the European Commission, the breast implants of the company PIP would not be linked to an increased risk to health, which makes their preventive withdrawal useless. The unauthorized gel used to limit the costs of the French company, liquidated in March 2010, was first singled out by the Medicines Agency (Ansm).
It has reported 74 cases of breast cancer and one very rare case of lymphoma in women with PIP prostheses, but the committee believes that, as of that date, “no increased health risk has been associated with exposure to silicone gel emanating from a PIP implant compared to other implants. “
No convincing data
This final opinion confirms a first expert appraisal carried out in 2012, recalls Le Figaro, that no reliable evidence of a ruptured PIP implant created a greater health risk than another breast implant. Despite the fact that “PIP implants have a much higher rupture rate than implants from other manufacturers”, SCENIHR therefore concludes that “there is no convincing data to justify routine removal of intact PIP implants. “
Among the 30,000 prosthesis wearers in France, nearly 17 411 had their PIP implants removed as a preventive measure, according to the latest report at the end of 2013.
